Clinical Trial Update: Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 [Phase 3]

View source ↗

Summary

Phase 3 trial update for Fontan Udenafil Exercise Longitudinal Assessment Trial-2 evaluating udenafil in single ventricle heart disease; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Single-ventricle Heart Disease

Drugs mentioned

• udenafil (udenafil)

Snippet

Sponsor: Mezzion Pharma Co. Ltd | Conditions: Single Ventricle Heart Disease | Phase 3 | Status: RECRUITING